One drug combination clears senescent and cancer cells
Senescent cells and cancer cells seem like opposites. But they share a key survival trick. A new drug combination exploits that overlap to eliminate both cell types at once.
Cells that are old and damaged stop dividing but also fail to die. They linger in tissues and secrete harmful signalling proteins, collectively called the SASP (senescence-associated secretory phenotype). These proteins raise chronic inflammation and can push nearby healthy cells into the same state. Cancer cells use related survival mechanisms to resist treatment. The researchers, publishing in Aging, describe how a combination of two compounds can kill both cell types simultaneously and extends the lives of old mice.
A shared vulnerability
The key lies in a shared weak point in cell survival. Both senescent cells and certain cancer cells depend on specific proteins that protect them from programmed cell death (apoptosis). By blocking those protective proteins, both cell types can be eliminated. The combination treatment was more effective in older mice than either compound alone, and mice lived longer after treatment.
Cautious optimism
The findings are so far based on animal models. Whether this approach is safe and effective in humans has not been studied. There are also risks: some senescent cells play a role in wound healing and tumour suppression. The researchers note that balancing these effects remains a challenge. From a longevity perspective, the combination strategy is interesting as a direction, suggesting that aging and cancer share related molecular pathways. Still, this is early-stage research, and the path to clinical use is long.
Want to research this yourself?
Search for example:
- SASP cellular senescence apoptosis
- senolytic cancer resistance
- apoptosis regulation senescent cells